NASDAQ:INVA
Innoviva, Inc Stock News
$15.98
+0 (+0%)
At Close: May 17, 2024
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
04:05pm, Tuesday, 06'th Jun 2023
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel
FDA approves Innoviva's bacterial pneumonia treatment
10:32pm, Tuesday, 23'rd May 2023
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that the U.S. Food and Drug Administration (FDA) approved XACDURO® (su
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, toda
Is Innoviva (INVA) Stock Undervalued Right Now?
11:28am, Monday, 17'th Apr 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Four Undervalued Healthcare Stocks for 2023
11:21am, Friday, 06'th Jan 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Should Value Investors Buy Innoviva (INVA) Stock?
02:40pm, Monday, 28'th Nov 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Should Value Investors Buy Innoviva (INVA) Stock?
11:17am, Monday, 28'th Nov 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Zacks.com featured highlights PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure
01:48pm, Friday, 18'th Nov 2022 Zacks Investment Research
PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure have been highlighted in this Screen of The Week article.
5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up
12:11pm, Thursday, 17'th Nov 2022 Zacks Investment Research
We have screened value stocks PBF, INVA, GLP, HCCI and STRL based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up
08:17am, Thursday, 17'th Nov 2022
We have screened value stocks PBF, INVA, GLP, HCCI and STRL based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
Are Investors Undervaluing Innoviva (INVA) Right Now?
02:40pm, Friday, 11'th Nov 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Investors Undervaluing Innoviva (INVA) Right Now?
11:17am, Friday, 11'th Nov 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
11:35pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates
08:19pm, Wednesday, 09'th Nov 2022
Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?